Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis
Abstract Background Whether pioglitazone may affect breast cancer risk in female diabetes patients is not conclusive and has not been investigated in the Asian populations. Methods The reimbursement database of Taiwan’s National Health Insurance was used to enroll an unmatched cohort and a propensit...
Main Author: | Chin-Hsiao Tseng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-022-09660-8 |
Similar Items
-
Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2022-12-01) -
Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study
by: Chin-Hsiao Tseng
Published: (2023-01-01) -
Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
by: M. V. Shestakova, et al.
Published: (2021-07-01) -
Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study
by: Min-Hee Woo, et al.
Published: (2019-05-01) -
Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
by: Jingxuan Lian, et al.
Published: (2022-02-01)